Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across ...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

The deal includes a $200m cash payment from AbbVie at closing, subject to standard adjustments, alongside potential interim funding payments. Credit: © AbbVie Inc ...

AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the pharmaceutical ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

This demo configures ESP32 NimBLE as a BLE client/central which connects to BLE HID servers/peripherals such as BLE mice. It has been tested with ESP32-NimBLE-Mouse and a real BLE trackball mouse. The ...